16220-99-8

Basic information

• Product Name: Benzoic acid, 5-(bromomethyl)-2-chloro-, methyl ester
• CAS NO: 16220-99-8
• Molecular Formula: C9H8BrClO2
• Molecular Weight: 263.518
• Mol File: 16220-99-8.mol

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 5-(bromomethyl)-2-chloro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-(bromomethyl)-2-chloro-, methyl ester(16220-99-8)
• EPA Substance Registry System: Benzoic acid, 5-(bromomethyl)-2-chloro-, methyl ester(16220-99-8)

Safety Data

• Hazardous Substances Data: 16220-99-8(Hazardous Substances Data)

Upstream product

• 16220-95-4 methyl 2-chloro-5-methylbenzoate 
• 6342-60-5 2-chloro-5-methyl-benzoic acid 
• 73129-52-9 2'-chloro-5-methylacetophenone 

Downstream Products

• 1256560-87-8 methyl 2-chloro-5-[(diethylamino)methyl]benzoate 
• 1422205-81-9 ethyl 2-chloro-5-(ethoxymethyl)benzoate 
• 90270-93-2 2-chloro-5-(hydroxymethyl)benzoic acid 
• 1401683-82-6 2-chloro-5-((2,4-dioxo-3,4-dihydroquinazoline-1(2H)-yl)methyl)benzoic acid 
• 1422205-80-8 2-chloro-5-(ethoxymethyl)benzoic acid 
• 1394349-40-6 2-chloro-5-[2-(2-trimethylsilanyl-ethoxy)-pyrimidin-4-ylmethyl]-benzoic acid methyl ester 
• 1394349-95-1 2-chloro-5-(2-methoxypyrimidine-4-carbonyl)benzoic acid methyl ester 
• 199679-23-7 2-chloro-5-formyl-benzoic acid methyl ester 

Relevant articles and documents

Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists

The P2X7 receptor is a promising target for the treatment of various diseases due to its significant role in inflammation and immune cell signaling. This work describes the design, synthesis, and in vitro evaluation of a series of novel derivatives bearing diverse scaffolds as potent P2X7 antagonists. Our approach was based on structural modifications of reported (adamantan-1-yl)methylbenzamides able to inhibit the receptor activation. The adamantane moieties and the amide bond were replaced, and the replacements were evaluated by a ligand-based pharmacophore model. The antagonistic potency of the synthesized analogues was assessed by two-electrode voltage clamp experiments, using Xenopus laevis oocytes that express the human P2X7 receptor. SAR studies suggested that the replacement of the adamantane ring by an aryl-cyclohexyl moiety afforded the most potent antagonists against the activation of the P2X7 cation channel, with analogue 2-chloro-N-[1-(3-(nitrooxymethyl)phenyl)cyclohexyl)methyl]benzamide (56) exhibiting the best potency with an IC50 value of 0.39 μΜ.

Water bridges are essential to neonicotinoids: Insights from synthesis, bioassay and molecular modelling studies

Water-bridged H-bonds have been observed in many cases of ligand-receptor recognitions. To explore the roles of water bridges in the binding of neonicotinoids with receptors, twenty-four neonicotinoid compounds with nine fragments, including 1H-1,2,3-tria

Discovery of quinazoline-2,4(1: H,3 H)-dione derivatives as novel PARP-1/2 inhibitors: Design, synthesis and their antitumor activity

Novel quinazoline-2,4(1H,3H)-dione derivatives bearing a 3-amino pyrrolidine moiety were designed and synthesized as PARP-1/2 inhibitors. Structure-activity relationships were examined which revealed a number of potent PARP-1/2 inhibitors with moderate se

BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to benzamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.

BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to benzamide derivatives of formula (I),wherein R1, R2, R3, R4, R5, R6, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.

METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS

The present invention relates to pyrimidine derivatives of Formula (Ia) and (Ib) (including tautomers, isomers, prodrugs, and pharmaceutically acceptable salts thereof). Said compounds are useful in the treatment of pain (such as neuropathic pain), inflammation, and epilepsy (by acting as anticonvulsants). Methods of medical treatment making use of said compounds, as well as additional compounds of Formula (IIa) and (IIb), are also disclosed.

Design, synthesis and identification of novel colchicine-derived immunosuppressant

Synthesis and biological evaluation of various colchicine analogues through the mixed-lymphocyte reaction (MLR), lymphoproliferation, and inhibitory effects on the inflammatory genes are described. In addition, a new series of immunosuppressive agents developed on the structural basis of colchicine, as well as their structure-activity relationships is reported. The most potent analogue 20a exhibited an excellent immunosuppressive activity on in vivo skin-allograft model, which is comparable to that of cyclosporin A.

SUBSTITUTED PYRROLE DERIVATIVE

The present invention provides a novel pyrrole derivative having excellent androgen receptor antagonism, which is represented by the formula (I): wherein R1represents a hydrogen atom, a cyano group or a group represented by the formula COORA (wherein RA represents an optional substituted C1-6 alkyl group), R2 and R4 are the same or different, and each represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a trifluoromethyl group, an amino-C1-6 alkyl group, a mono-or di-substituted amino-C1-6 alkyl group, an optionally halogenated C1-6 alkyl group substituted with an optionally substituted hydroxyl group, a C2-6 alkenyl group substituted with an optionally substituted hydroxyl group, a C1-6 alkyl group substituted with an optionally substituted and optionally oxidized thiol group, an optionally substituted with and optionally oxidized thiol group, a cyano group, an acyl group, an optionally substituted oxazolyl group or a 1,3-dioxolan-2-yl group, R3 represents a group represented by the formula (a): (wherein X represents a halogen atom, Y represents a carbon atom or a nitrogen atom, Alk represents an optionally substituted C 1-4 alkylene group, and RB represents a hydrogen atom or an acyl group), and R5 represents a phenyl group which has a cyano group at a 4-position or a 3-position thereof, and may be further substituted, or a salt thereof. The present invention also provides an androgen receptor antagonist containing the pyrrole derivative, or a salt thereof.